Panacea Biotec Limited (PANACEABIO.NS)

INR 544.6

(-1.37%)

Operating Income Summary of Panacea Biotec Limited

Panacea Biotec Limited's latest annual operating income in 2023 was - INR , up 44.74% from previous year.
Panacea Biotec Limited's latest quarterly operating income in 2024 Q1 was -227.2 Million INR , down -53.0% from previous quarter.
Panacea Biotec Limited reported an annual operating income of -1.02 Billion INR in 2022, down -112.19% from previous year.
Panacea Biotec Limited reported an annual operating income of -484.18 Million INR in 2021, down -213.3% from previous year.
Panacea Biotec Limited reported a quarterly operating income of -567.7 Million INR for 2023 FY, up 44.74% from previous quarter.
Panacea Biotec Limited reported a quarterly operating income of -137.1 Million INR for 2023 Q1, up 47.95% from previous quarter.

Annual Operating Income Chart of Panacea Biotec Limited (2023 - 2004)

Historical Annual Operating Income of Panacea Biotec Limited (2023 - 2004)

Year	Operating Income	Operating Income Growth
2023	- INR	44.74%
2022	-1.02 Billion INR	-112.19%
2021	-484.18 Million INR	-213.3%
2020	427.33 Million INR	-0.45%
2019	429.26 Million INR	138.83%
2018	-1.1 Billion INR	-389.43%
2017	381.96 Million INR	167.34%
2016	-567.2 Million INR	-199.63%
2015	-189.3 Million INR	80.96%
2014	-994.1 Million INR	10.41%
2013	-1.1 Billion INR	56.15%
2012	-2.53 Billion INR	-148.71%
2011	-1.01 Billion INR	-149.3%
2010	2.06 Billion INR	32.62%
2009	1.55 Billion INR	401.17%
2008	-516.69 Million INR	-125.46%
2007	2.02 Billion INR	-11.45%
2006	2.29 Billion INR	103.23%
2005	1.12 Billion INR	109.95%
2004	537.08 Million INR	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-227.2 Million INR	-53.0%
2023 FY	-567.7 Million INR	44.74%
2023 Q1	-137.1 Million INR	47.95%
2023 Q2	-96.4 Million INR	29.69%
2023 Q3	-92.6 Million INR	3.94%
2023 Q4	-148.5 Million INR	-60.37%
2022 Q2	-32.8 Million INR	95.78%
2022 Q4	-263.4 Million INR	-168.59%
2022 FY	-1.02 Billion INR	-112.19%
2022 Q1	-776.5 Million INR	-98.3%
2022 Q3	384 Million INR	1270.73%
2021 Q4	-391.58 Million INR	-1418.45%
2021 FY	-484.18 Million INR	-213.3%
2021 Q3	29.7 Million INR	204.21%
2021 Q1	-126.1 Million INR	-154.23%
2021 Q2	-28.5 Million INR	77.4%
2020 FY	427.33 Million INR	-0.45%
2020 Q4	-49.6 Million INR	-229.17%
2020 Q3	38.4 Million INR	-85.58%
2020 Q2	266.3 Million INR	137.56%
2020 Q1	112.1 Million INR	-16.34%
2019 Q2	-170.8 Million INR	-242.1%
2019 Q3	261.1 Million INR	252.87%
2019 Q4	133.99 Million INR	-48.68%
2019 FY	429.26 Million INR	138.83%
2019 Q1	120.2 Million INR	146.99%
2018 Q4	-255.81 Million INR	3.07%
2018 Q2	-234 Million INR	20.41%
2018 Q1	-294 Million INR	0.0%
2018 FY	-1.1 Billion INR	-389.43%
2018 Q3	-263.9 Million INR	-12.78%
2017 FY	381.96 Million INR	167.34%
2016 FY	-567.2 Million INR	-199.63%
2015 FY	-189.3 Million INR	80.96%
2014 FY	-994.1 Million INR	10.41%
2013 FY	-1.1 Billion INR	56.15%
2012 FY	-2.53 Billion INR	-148.71%
2011 FY	-1.01 Billion INR	-149.3%
2010 FY	2.06 Billion INR	32.62%
2009 FY	1.55 Billion INR	401.17%
2008 FY	-516.69 Million INR	-125.46%
2007 FY	2.02 Billion INR	-11.45%
2006 FY	2.29 Billion INR	103.23%
2005 FY	1.12 Billion INR	109.95%
2004 FY	537.08 Million INR	0.0%

Peer Operating Income Comparison of Panacea Biotec Limited

Name	Operating Income	Operating Income Difference
Biocon Limited	50.83 Billion INR	100.0%
Blue Jet Healthcare Limited	3.37 Billion INR	100.0%
Concord Biotech Limited	6.26 Billion INR	100.0%
Dishman Carbogen Amcis Limited	-413 Million INR	100.0%
Jubilant Ingrevia Limited	2.93 Billion INR	100.0%
Lyka Labs Limited	29.13 Million INR	100.0%
Piramal Pharma Limited	4.31 Billion INR	100.0%
SMS Lifesciences India Limited	359.47 Million INR	100.0%
Supriya Lifescience Limited	1.57 Billion INR	100.0%
Syngene International Limited	6.46 Billion INR	100.0%
TAKE Solutions Limited	-213.49 Million INR	100.0%
Zota Health Care Limited	-129.79 Million INR	100.0%